Association of Androgen Receptor, Prostate-Specific Antigen, and CYP19 Gene Polymorphisms with Prostate Carcinoma and Benign Prostatic Hyperplasia in a North Indian Population

被引:13
|
作者
Soni, Abha [1 ]
Bansal, Anju [1 ]
Mishra, Ashwani Kumar [1 ]
Batra, Jyotsna [2 ,3 ]
Singh, Laishram Chandreshwor [1 ]
Chakraborty, Anurupa [1 ]
Yadav, Dhirendra Singh [1 ]
Mohanty, Nayan K. [4 ,5 ]
Saxena, Sunita [1 ]
机构
[1] Natl Inst Pathol ICMR, New Delhi 110029, India
[2] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4001, Australia
[3] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia
[4] Safdarjang Hosp, Dept Urol, New Delhi, India
[5] Vardhman Mahavir Med Coll, New Delhi, India
基金
澳大利亚国家健康与医学研究理事会;
关键词
CAG REPEAT LENGTH; CANCER; RISK; AROMATASE; PSA; IDENTIFICATION; EXPRESSION; IMPACT; GGN;
D O I
10.1089/gtmb.2011.0322
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The genes involved in androgen pathway and metabolism have been reported to contribute considerably to prostate carcinoma (CaP) risk. The present study investigated the association of androgen receptor (AR), prostate-specific antigen (PSA or KLK3), and cytochrome P450 (CYP19) gene polymorphisms in CaP (n = 105) and benign prostatic hyperplasia (BPH) (n = 120) in comparison to normal healthy controls (n = 106) in an Indian population. We also evaluated the functional consequences of these gene variants on AR and PSA mRNA expression. Significant association of short AR CAG repeats (<= 24) with risk of CaP (odds ratios [OR] = 2.98, p < 0.001) and BPH (OR = 1.96, p = 0.01) was observed; however, CYP19 gene polymorphism was not found to be associated with disease phenotype (p > 0.05). PSA G-158A SNP was found to be significantly associated with risk of CaP (AA: OR = 2.68, p = 0.016 and GA: OR = 2.07, p = 0.018) p-trend 0.031 and BPH (AA: OR = 3.46, p < 0.001 and GA: OR = 2.47, p = 0.03) p-trend 0.009, respectively. PSA G-158A genotype independently increased the risk of developing BPH (OR = 16.37, p < 0.001), irrespective of AR CAG repeat length. Using quantitative real-time polymerase chain reaction, we found a significant upregulation of AR and PSA mRNA expression in CaP comparison to BPH. While short AR CAG (<= 24) repeats were associated with higher AR mRNA expression in CaP (p = 0.002), the PSA SNP did not correlate with its mRNA expression. Interestingly, significantly higher risk estimates for CaP were observed for the combined analysis of short AR CAG and CYP19 genotypes (A2A2) (OR = 7.18, p < 0.001) or A2A3 (OR = 7.60, p = 0.004). Our results suggest significant association of androgen signaling gene polymorphisms with risk of CaP and BPH and provide evidence for a putative functional role of AR CAG repeat in regulating its mRNA expression and warrant the need of larger studies in the Indian population to confirm our results.
引用
收藏
页码:835 / 840
页数:6
相关论文
共 50 条
  • [21] RESPONSE OF PROSTATE VOLUME, PROSTATE-SPECIFIC ANTIGEN, AND TESTOSTERONE TO FLUTAMIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
    STONE, NN
    CLEJAN, SJ
    JOURNAL OF ANDROLOGY, 1991, 12 (06): : 376 - 380
  • [22] Impact of Treatment With Statins on Prostate-Specific Antigen and Prostate Volume in Patients With Benign Prostatic Hyperplasia
    Lee, Sang Hun
    Park, Tae Ju
    Bae, Min Ho
    Choi, Sung Ho
    Cho, Young Sam
    Joo, Kwan Joong
    Kwon, Chil Hun
    Park, Heung Jae
    KOREAN JOURNAL OF UROLOGY, 2013, 54 (11) : 750 - 755
  • [23] Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia
    Hochberg, DA
    Armenakas, NA
    Fracchia, JA
    PROSTATE, 2000, 45 (04): : 315 - 319
  • [24] Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia
    Putra, Ida Bagus O. W.
    Hamid, Agus R. A. H.
    Mochtar, Chaidir A.
    Umbas, Rainy
    PROSTATE INTERNATIONAL, 2016, 4 (02) : 43 - 48
  • [25] Relationship of age, prostate-specific antigen, and prostate volume in indonesian men with benign prostatic hyperplasia
    Putra, I. B. O. W.
    Hamid, A. R. A. H.
    Mochtar, C. A.
    Umbas, R.
    BJU INTERNATIONAL, 2014, 114 : 7 - 7
  • [26] Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia
    Mochtar, CA
    Kiemeney, LALM
    van Riemsdijk, MM
    Barnett, GS
    Laguna, MP
    Debruyne, FMJ
    de la Rosette, JJMCH
    EUROPEAN UROLOGY, 2003, 44 (06) : 695 - 700
  • [27] EVALUATION OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC ACID-PHOSPHATASE IN UNTREATED PROSTATIC-CARCINOMA AND BENIGN PROSTATIC HYPERPLASIA
    BOGDANOWICZ, JFAT
    BENTVELSEN, FM
    OOSTEROM, R
    SCHROEDER, FH
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1991, : 97 - 103
  • [28] Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level
    Punglia, RS
    D'Amico, AV
    Catalona, WJ
    Roehl, KA
    Kuntz, KM
    CANCER, 2006, 106 (07) : 1507 - 1513
  • [29] Association of LTβR gene polymorphisms with prostate volume in benign prostatic hyperplasia in the Korean population
    Lee, S. H.
    Kim, S. K.
    Yoo, K. H.
    Chung, J. H.
    Chang, S. G.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) : 18607 - 18615
  • [30] Prostate specific antigen (PSA) levels in health, prostatic carcinoma and benign prostatic hyperplasia
    Dosoo, D. K.
    Botchway, F. A.
    Adu-Gyamfi, C.
    Amanquah, S. D.
    CLINICAL CHEMISTRY, 2006, 52 (06) : A166 - A166